Lungcancer
7
1
1
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
14%
1 trials in Phase 3/4
20%
1 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (7)
Effects of Preoperative Rehabilitation in Patients Resected for Lung Cancer
A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung
Prospective Screening and Differentiating Common Cancers Using Peripheral Blood Cell-Free DNA Sequencing
Imaging Multiparametric/Multimodality for Lungcancer
SHOX2_PTGER4 DNA Methlyation in Lung Cancer
Effect Of Ketamine Infusion In Patients With COPD Applied One Lung Ventilation
HD+ I-scan Bronchoscopy Vascular Abnormalities Detection Multicenter Study